Home/Pipeline/ASP-001

ASP-001

Erectile Dysfunction

ApprovedActive

Key Facts

Indication

Erectile Dysfunction

Phase

Approved

Status

Active

Company

Aspargo Laboratories

About Aspargo Laboratories

Aspargo Laboratories, founded in 2018 and headquartered in Cambridge, USA, is a private biotech company developing a platform for oral suspension drug reformulation. Its lead asset, ASP-001 (liquid sildenafil), is commercially available in several European countries and has completed clinical trials for an FDA NDA submission. The company's strategy leverages its suspension technology to enhance bioavailability and patient adherence, with a future vision that includes a connected device platform for personalized dosing and data tracking across multiple medications.

View full company profile

Therapeutic Areas

Oncology Immunology Urology

Other Erectile Dysfunction Drugs

Drug	Company	Phase	Status
CF602	Can Fite Biopharma	Preclinical	Active
E300 ESWT System	Wikkon	Commercial	Market Released
Sildenafil Citrate	Azico Biophore	Commercial	Active
Sildenafil Formulation	InnovaZone Labs	Approved	Active
Rigi10™ Malleable Penile Prosthesis	Rigicon	Approved	Commercial
UNITED Study (Investigational Inflatable Penile Prosthesis)	Rigicon	Clinical Investigation	Active
Sildenafil-loaded Z-pods®	Atticus Pharma	Pre-clinical	Active
FGF-based Therapeutic	Venturis Therapeutics	Pre-clinical	Active
TPN171 (Simenafil hydrochloride) Tablets	Vigonvita	Approved	Marketed in China and Uzbekistan
DehydraTECH-sildenafil	Lexaria Bioscience	Human Clinical	Active